273 related articles for article (PubMed ID: 18374419)
1. In vitro measurements of metabolism for application in pharmacokinetic modeling.
Lipscomb JC; Poet TS
Pharmacol Ther; 2008 Apr; 118(1):82-103. PubMed ID: 18374419
[TBL] [Abstract][Full Text] [Related]
2. PBPK models in risk assessment--A focus on chloroprene.
DeWoskin RS
Chem Biol Interact; 2007 Mar; 166(1-3):352-9. PubMed ID: 17324392
[TBL] [Abstract][Full Text] [Related]
3. Development and application of physiologically based pharmacokinetic-modeling tools to support drug discovery.
Lüpfert C; Reichel A
Chem Biodivers; 2005 Nov; 2(11):1462-86. PubMed ID: 17191947
[TBL] [Abstract][Full Text] [Related]
4. Physiologically based pharmacokinetics (PBPK).
Espié P; Tytgat D; Sargentini-Maier ML; Poggesi I; Watelet JB
Drug Metab Rev; 2009; 41(3):391-407. PubMed ID: 19601719
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of an integrated in vitro-in silico PBPK (physiologically based pharmacokinetic) model to provide estimates of human bioavailability.
Cai H; Stoner C; Reddy A; Freiwald S; Smith D; Winters R; Stankovic C; Surendran N
Int J Pharm; 2006 Feb; 308(1-2):133-9. PubMed ID: 16352407
[TBL] [Abstract][Full Text] [Related]
6. The U.S. Environmental Protection Agency's risk assessment guidelines.
Jarabek AM; Farland WH
Toxicol Ind Health; 1990 Oct; 6(5):199-216. PubMed ID: 2274984
[TBL] [Abstract][Full Text] [Related]
7. Research on risk assessment and risk management: future directions.
Grant LD; Jarabek AM
Toxicol Ind Health; 1990 Oct; 6(5):217-33. PubMed ID: 2274985
[TBL] [Abstract][Full Text] [Related]
8. Physiologically based approaches towards the prediction of pharmacokinetics: in vitro-in vivo extrapolation.
De Buck SS; Mackie CE
Expert Opin Drug Metab Toxicol; 2007 Dec; 3(6):865-78. PubMed ID: 18028030
[TBL] [Abstract][Full Text] [Related]
9. Blood concentrations of acrylonitrile in humans after oral administration extrapolated from in vivo rat pharmacokinetics, in vitro human metabolism, and physiologically based pharmacokinetic modeling.
Takano R; Murayama N; Horiuchi K; Kitajima M; Kumamoto M; Shono F; Yamazaki H
Regul Toxicol Pharmacol; 2010 Nov; 58(2):252-8. PubMed ID: 20600458
[TBL] [Abstract][Full Text] [Related]
10. Predicting human pharmacokinetics from preclinical data.
Poggesi I
Curr Opin Drug Discov Devel; 2004 Jan; 7(1):100-11. PubMed ID: 14982153
[TBL] [Abstract][Full Text] [Related]
11. Steady-state solutions to PBPK models and their applications to risk assessment I: Route-to-route extrapolation of volatile chemicals.
Chiu WA; White P
Risk Anal; 2006 Jun; 26(3):769-80. PubMed ID: 16834633
[TBL] [Abstract][Full Text] [Related]
12. Prediction of human pharmacokinetics - renal metabolic and excretion clearance.
Fagerholm U
J Pharm Pharmacol; 2007 Nov; 59(11):1463-71. PubMed ID: 17976256
[TBL] [Abstract][Full Text] [Related]
13. Development and specification of physiologically based pharmacokinetic models for use in risk assessment.
Clewell RA; Clewell HJ
Regul Toxicol Pharmacol; 2008 Feb; 50(1):129-43. PubMed ID: 18077066
[TBL] [Abstract][Full Text] [Related]
14. Physiologically based pharmacokinetic (PBPK) modeling and simulation: applications in lead optimization.
Peters SA; Ungell AL; Dolgos H
Curr Opin Drug Discov Devel; 2009 Jul; 12(4):509-18. PubMed ID: 19562647
[TBL] [Abstract][Full Text] [Related]
15. [Advances and related issues in the use of in vitro methods to predict metabolic clearance rate of new drugs].
Zhang Q; Wang GJ
Yao Xue Xue Bao; 2007 Oct; 42(10):1023-8. PubMed ID: 18229605
[TBL] [Abstract][Full Text] [Related]
16. Physiologically-based pharmacokinetic modeling of genistein in rats, Part I: Model development.
Schlosser PM; Borghoff SJ; Coldham NG; David JA; Ghosh SK
Risk Anal; 2006 Apr; 26(2):483-500. PubMed ID: 16573635
[TBL] [Abstract][Full Text] [Related]
17. On nonoscillation and monotonicity of solutions of nonnegative and compartmental dynamical systems.
Chellaboina V; Haddad WM; Bailey JM; Ramakrishnan J
IEEE Trans Biomed Eng; 2004 Mar; 51(3):408-14. PubMed ID: 15000372
[TBL] [Abstract][Full Text] [Related]
18. Using ontogeny information to build predictive models for drug elimination.
Alcorn J; McNamara PJ
Drug Discov Today; 2008 Jun; 13(11-12):507-12. PubMed ID: 18549977
[TBL] [Abstract][Full Text] [Related]
19. Using in vitro human tissues to predict pharmacokinetic properties.
Huebert ND; Dasgupta M; Chen Y
Curr Opin Drug Discov Devel; 2004 Jan; 7(1):69-74. PubMed ID: 14982150
[TBL] [Abstract][Full Text] [Related]
20. Quantitative pharmacology or pharmacokinetic pharmacodynamic integration should be a vital component in integrative pharmacology.
Gabrielsson J; Green AR
J Pharmacol Exp Ther; 2009 Dec; 331(3):767-74. PubMed ID: 19779129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
